To evaluate associations of [ 11 C]Pittsburgh compound B (PIB) and [ 18 F]FDDNP with impairment in specific cognitive domains over the broader spectrum comprising cognitively normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD).
measure the amount of fibrillar A␤ deposits, 6, 7 whereas [ 18 F]FDDNP has been reported to label not only amyloid but also other proteins, 8 including neurofibrillary tangles. 9 Recently, using a paired study in the same subjects, we have shown that both tracers were able to distinguish patients with AD from cognitively normal elderly subjects at a group level, although [ 11 C]PIB had the largest discriminative power. 10 To date, several studies have reported associations between increased [ 11 C]PIB binding and episodic memory impairment in cognitively normal elderly subjects and patients with MCI. 4, 11, 12 For [ 18 F]FDDNP, associations between increased frontal, temporal, and parietal binding and impairment of memory have been found. 5, 13 At present, no studies have been performed evaluating relationships between tracer binding and cognitive impairment using both tracers in the same subjects. The aim of this study was to assess the independent associations of [ 11 C]PIB and [ 18 F]FDDNP with impairment in the cognitive domains of memory, language, executive functioning, and visuoconstructive praxis over the spectrum comprising cognitively normal elderly subjects, patients with MCI, and patients with AD.
METHODS Subjects. Twelve patients with AD, 13 patients with amnestic MCI, and 15 age-matched cognitively normal elderly subjects, for which paired [ 11 C]PIB and [ 18 F]FDDNP scans and neuropsychological data were available, were included between November 2005 and September 2008. Global and regional [ 11 C]PIB and [ 18 F]FDDNP binding of an overlapping sample have been presented before. 10 All patients received a standard dementia screening that included medical history, physical and neurologic examinations, screening laboratory tests, and brain MRI. Clinical diagnosis was established by consensus in a multidisciplinary team, without knowledge of PET results. All patients with AD met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. 3 Patients with MCI met Petersen criteria based on subjective and objective cognitive impairment, predominantly affecting memory, in the absence of dementia or significant functional impairment. 2 Cognitively normal elderly subjects were recruited through advertisements in newspapers and underwent the same diagnostic procedures. The level of education was classified using the system of Verhage, 14 ranging from 1 (low) to 7 (high). Exclusion criteria were history of major psychiatric or neurologic (other than AD) illness and use of nonsteroidal anti-inflammatory drugs, because these have been reported to compete with [ 18 F]FDDNP for binding to A␤ fibrils in vitro and to A␤ plaques ex vivo. 15 Additional exclusion criteria for cognitively normal elderly subjects were subjective memory symptoms or clinically significant abnormalities on the MRI scan (as determined by a neuroradiologist).
Standard protocol approvals, registrations, and patient consents. Written informed consent was obtained from all subjects after a complete written and verbal description of the study. The study was approved by the Medical Ethics Review Committee of the VU University Medical Centre Amsterdam.
Neuropsychological assessment. Detailed neuropsychological assessment was performed using the following tests: Mini-Mental State Examination (MMSE), 16 Digit Span, 17 immediate and delayed recall of the Dutch version of the Rey Auditory Verbal Learning Task (RAVLT), 18 Visual Association Test (VAT) 19 21 The median time between imaging and neuropsychological assessment was 0.9 months (interquartile range, 1.6 months), with a mean (ϮSD) of 1.2 Ϯ 1.3 months.
PET. PET scans were performed using an ECAT EXACT
HRϩ scanner 22 (Siemens/CTI, Knoxville, TN), equipped with a neuroinsert to reduce the contribution of outside field of view (FOV) activity. This scanner enables the acquisition of 63 transaxial planes over a 15.5 cm axial FOV, thus allowing the whole brain to be imaged in a single bed position. All subjects received a venous cannula for tracer injection. Patient motion was restricted by the use of a head holder and monitored by checking the position of the head using laser beams.
First, a 10-minute transmission scan was performed in 2-dimensional acquisition mode using 3 retractable rotating line sources. This scan was used to correct the subsequent emission scan for photon attenuation. Next, a dynamic emission scan in 3-dimensional acquisition mode was started simultaneously with the IV injection of 353 Ϯ 71 MBq [ 11 C]PIB with a specific activity (SA) of 43 Ϯ 24 GBq/mol. Using an infusion pump (Med-Rad, Beek, The Netherlands), activity was injected in approximately 4 seconds, which was followed by a flush of 40 mL saline at 2.0 mL/s. Radiolabeled [ 11 C]PIB was synthesized according to a modification 23 of the procedure described by Wilson et al. 24 Each dynamic emission scan consisted of 23 frames with progressive increase in frame length (1 ϫ 15, 3 ϫ 5, 3 ϫ 10, 2 ϫ 30, 3 ϫ 60, 2 ϫ 150, 2 ϫ 300, 7 ϫ 600 s) and a total duration of 90 minutes.
After a resting period of at least 1 hour to allow for decay of 11 C (i.e., approximately 2.5 hours after the administration of 
MRI.
All subjects underwent a structural MRI scan using a Siemens 1.5-T Sonata scanner (Siemens Medical Solutions, Erlangen, Germany). The scan protocol included a coronal T1weighted 3-dimensional magnetization prepared rapid acquisition gradient echo (slice thickness 1.5 mm, 160 slices; matrix size 256 ϫ 256; voxel size 1 ϫ 1 ϫ 1.5 mm; echo time 3.97 ms; repetition time 2,700 ms; inversion time ϭ 950 ms; flip angle 8°).
Image analysis.
All PET sinograms were corrected for dead time, tissue attenuation using the transmission scan, decay, scatter, and randoms, and were reconstructed using a standard filtered back projection algorithm and a Hanning filter with cutoff at 0.5 times the Nyquist frequency. A zoom factor of 2 and a matrix size of 256 ϫ 256 ϫ 63 were used, resulting in a voxel size of 1.2 ϫ 1.2 ϫ 2.4 mm and a spatial resolution of approximately 7 mm full-width at half-maximum at the center of the FOV.
Magnetic resonance (MR) images were aligned to corresponding PET images using a mutual information algorithm. 26 Segmentation of MR images and further analysis of PET data were performed using PVE lab, a software program that uses a probability map of 35 delineated (gray matter) regions of interest (ROIs) that has been validated previously. 27 No correction for partial volume effects was applied to the PET data.
ROIs were projected onto [ 11 C]PIB and [ 18 F]FDDNP parametric images of binding potential (BP ND ). These parametric images were generated by applying a basis function implementation of the "2-step" simplified reference tissue model with cerebellar gray matter as reference tissue (RPM2) 28 to the full dynamic 90-minute PET data. 29, 30 BP ND is a quantitative measure of specific binding, reflecting the concentration of specifically bound tracer relative to the concentration of free and nonspecifically bound tracer in tissue under equilibrium conditions. 31 A global cortical ROI was defined, based on a volume weighted BP ND average of the following ROIs: frontal (volume weighted average of orbital frontal, medial inferior frontal, and superior frontal), parietal, temporal (volume weighted average of superior temporal and medial inferior temporal) cortex, medial temporal lobe (MTL; volume weighted average of entorhinal cortex and hippocampus), and posterior cingulate. Mean (ϮSD) volumes for the ROIs were as follows: frontal, 55 Ϯ 9 mL; parietal, 26 Ϯ 5 mL; temporal, 41 Ϯ 7 mL; MTL, 5 Ϯ 1 mL; and posterior cingulate, 3 Ϯ 1 mL. Cerebellar gray matter was chosen as reference tissue because of its (histopathologic) lack of Congo red and thioflavin-S-positive plaques. 32, 33 Statistical analysis. Data are presented as mean ϮSD, unless otherwise stated. Data of TMT and Stroop tests were log transformed because they were not normally distributed. Frequency distributions for sex were compared with 2 tests. For continuous measures, differences between groups were assessed using analysis of variance with age and sex as covariates and post hoc least significant difference tests.
Pearson correlations were calculated for global and regional [ 11 C]PIB and [ 18 F]FDDNP binding. For assessment of relationships between global BP ND data and neuropsychological tests, linear regression analyses were performed. Standardized ␤ values and standard errors are reported to allow comparison of effect sizes. R 2 values are given for each model. In the first model, the relationship of each PET ligand (independent variable) with each cognitive test (dependent variable) was assessed separately, after adjustment for age and sex. In the second model, both PET ligands were entered simultaneously (independent variables), after adjustment for age and sex. In the third model, the same relationships were examined as in the second model, additionally adjusted for diagnosis (using dummy variables).
Subsequently, an additional analysis was performed to evaluate the relationships between regionally increased ligand binding and performance on neuropsychological tests. After adjustment for age and sex (forced entry), forward step regression analysis was performed with regional [ 11 (table 1) . Across the diagnostic groups, global binding of the 2 ligands was moderately correlated (table 2). When regional binding was assessed, similar correlations were found for frontal and parietal ROIs, but poor correlations were found for temporal, medial temporal, and posterior cingulate ROIs.
Linear regression analyses showed that, adjusted for age and sex, higher global [ 11 figure) .
Finally, forward step regression analysis was used to assess associations between regional binding BP ND values and cognitive test performance ( binding was associated specifically with impairment of episodic memory, whereas increased [ 11 C]PIB binding was associated with impairment in a broader range of cognitive functions, especially memory impairment and executive dysfunctioning.
Other studies have presented associations with either increased [ 11 C]PIB 11, 12, 34 or increased [ 18 F]FDDNP binding. 5, 13 Increased [ 11 C]PIB binding was associated with both impaired memory performance and impaired nonmemory functions. 11 Increased [ 18 F]FDDNP signal was found to be associated with decreased composite cognitive score. 13 In the present study, [ 11 C]PIB and [ 18 F]FDDNP binding were simultaneously evaluated, revealing both ligands to be independently associated with impaired cognition. Higher global [ 11 C]PIB was independently associated with impairment in a number of cognitive domains, whereas higher global [ 18 F]FDDNP was associated specifically with episodic memory impairment.
Although no specific associations between memory and amyloid load in the brain at postmortem examinations have been reported, amyloid deposition in general is associated with a high likelihood of presence of AD. This seemingly is in line with the more widespread impairment in cognition associated with increased global [ 11 C]PIB binding. The specific association between [ 18 F]FDDNP binding and episodic memory impairment, when simultaneously assessing the ligands, is somewhat less straightforward. However, part of the specific signal of [ 18 F]FDDNP may be due to the tangle component. 35 Apart from differences in underlying substrate for tracer binding, an alternative explanation for the difference in associations between [ 11 C]PIB and [ 18 F]FDDNP could be the higher specific signal of [ 11 C]PIB. As a result, differences between diagnostic groups were larger and may have driven the observed associations with cognitive functioning. When additional adjustments for diagnosis were performed, association between global binding and episodic memory remained for both tracers. This implies that even after accounting for a diagnosis effect, both amyloid and tangle burden, as estimated using PET, contributed to impairment in episodic memory, the main characteristic of (prodromal) AD. 1 When regional binding was assessed, frontal, temporal, and posterior cingulate [ 11 C]PIB binding and frontal [ 18 F]FDDNP binding were associated with memory function, whereas parietal [ 11 C]PIB binding was associated with nonmemory domains of language, executive functioning, and visuoconstructive praxis. These findings suggest that the association with impairment in specific cognitive domains is at least partly driven by regional tracer uptake.
A limitation of the present study is the relatively small sample size, possibly concealing subtle associations. Nevertheless, the unique design, performing quantitative PET scanning with both ligands and neuropsychological tests in the same subjects along the spectrum of cognitive decline, enabled a direct evaluation of the independent association of both tracers with impairment in specific cognitive domains.
The present findings demonstrate that higher binding of both [ 11 C]PIB and [ 18 F]FDDNP is associated with cognitive impairment. This has relevance in the discussion on using biomarkers to identify the prodromal phase of AD 36 
